515 related articles for article (PubMed ID: 25164566)
1. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
[TBL] [Abstract][Full Text] [Related]
2. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
Dong B; Wu M; Cao A; Li H; Liu J
Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
[TBL] [Abstract][Full Text] [Related]
4. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
[TBL] [Abstract][Full Text] [Related]
5. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
6. Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells.
Chen HC; Chen PY; Wu MJ; Tai MH; Yen JH
PLoS One; 2016; 11(9):e0162414. PubMed ID: 27617748
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
8. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
Dong B; Wu M; Li H; Kraemer FB; Adeli K; Seidah NG; Park SW; Liu J
J Lipid Res; 2010 Jun; 51(6):1486-95. PubMed ID: 20048381
[TBL] [Abstract][Full Text] [Related]
9. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
11. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
[TBL] [Abstract][Full Text] [Related]
12. The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (
Chang HY; Wu JR; Gao WY; Lin HR; Chen PY; Chen CI; Wu MJ; Yen JH
Molecules; 2019 Jan; 24(3):. PubMed ID: 30704067
[TBL] [Abstract][Full Text] [Related]
13. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
[TBL] [Abstract][Full Text] [Related]
14. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
16. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
[TBL] [Abstract][Full Text] [Related]
17. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
18. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
[TBL] [Abstract][Full Text] [Related]
19. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
[TBL] [Abstract][Full Text] [Related]
20. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.
Cameron J; Holla ØL; Ranheim T; Kulseth MA; Berge KE; Leren TP
Hum Mol Genet; 2006 May; 15(9):1551-8. PubMed ID: 16571601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
